Appropriate use of PCSK9 Inhibitors in India
Iyengar, S.S.; Bansal, M.; Sawhney, J.; Wander, G.; Narasingan, S.N.; Chandra, K.S.; D, P.; Nair, T.; Krishnakumar, B.; Deshpande, N.; Bardoloi, N.; Shetty, S.; Desai, N.; Pancholia, A.K.; Swamy, A.
Journal of the Association of Physicians of India 67(4): 74-85
2019
ISSN/ISBN: 0004-5772 PMID: 31311223 Document Number: 698043
The burden of atherosclerotic cardiovascular (CV) disease is alarmingly high and increasing in our country. Dyslipidemia is one of the major modifiable risk factors, and INTERHEART study showed that dyslipidemia had the highest population attributable risk for myocardial infarction. In the management of dyslipidemia, low-density lipoprotein cholesterol (LDL-C) is the primary therapeutic target. In addition to therapeutic lifestyle changes, statins and ezetimibe effectively lower LDL-C and consequently improve CV outcomes. However, there are situations where these drugs fall short of achieving the target or they may not be well tolerated.